Skip to main content
    G

    Galectin Therapeutics Inc (GALT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.02
    -0.03 (-0.98%)

    Market Cap: $307.59M

    Last updated: Nov 17, 2026 at 11:02 AM ET

    Galectin Therapeutics Inc (GALT) Earnings: Report Dates and Results

    Updated Aug 14, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Galectin Therapeutics (GALT) is expected to report earnings on Mar 29, 2027. In the quarter ended Jun 30, 2026, Galectin Therapeutics reported EPS of -$0.14, below the -$0.09 estimate. It beat the EPS estimate in 3 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    56%(22/39)
    Avg Surprise
    +1.62%

    Upcoming Estimates

    Reports Mar 29, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.05
    Range-$0.05 - -$0.05
    3 analysts
    Revenue Consensus
    N/A
    RangeN/A
    3 analysts

    Next Report

    GALT has an expected report date of Mar 29, 2027.

    Earnings History

    Of the 40 quarters below that had an estimate, GALT beat 23, missed 13 and matched 4. The widest gap in the table came in the quarter ended Dec 31, 2019, when EPS landed 100.00% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReported
    Jun 30, 2026-$0.14-$0.09-$0.09 - -$0.09-55.56%MissN/A10 up, 0 downAug 14, 2026
    Mar 31, 2026-$0.08-$0.06-$0.06 - -$0.06-33.33%MissN/A10 up, 0 downMay 15, 2026
    Dec 31, 2025-$0.08-$0.10-$0.10 - -$0.10+20.00%BeatN/A11 up, 0 downMar 31, 2026
    Sep 30, 2025-$0.13-$0.11-$0.11 - -$0.11-18.18%MissN/A11 up, 0 downNov 14, 2025
    Jun 30, 2025-$0.12-$0.16N/A+25.00%BeatN/AN/A0 up, 0 downAug 14, 2025
    Mar 31, 2025-$0.15-$0.11N/A-36.36%MissN/AN/A0 up, 0 downMay 15, 2025
    Dec 31, 2024-$0.19-$0.16N/A-18.75%MissN/AN/A0 up, 0 downMar 31, 2025
    Sep 30, 2024-$0.18-$0.20-$0.20 - -$0.20+10.00%BeatN/A10 up, 0 downNov 14, 2024
    Jun 30, 2024-$0.20-$0.16N/A-25.00%MissN/AN/A0 up, 0 downAug 13, 2024
    Mar 31, 2024-$0.19-$0.16-$0.16 - -$0.16-18.75%MissN/A10 up, 0 downMay 15, 2024
    Dec 31, 2023-$0.16-$0.16N/A0.00%In lineN/AN/A0 up, 0 downMar 29, 2024
    Sep 30, 2023-$0.24-$0.16-$0.16 - -$0.16-50.00%MissN/A10 up, 0 downNov 13, 2023
    Jun 30, 2023-$0.15-$0.21N/A+28.57%BeatN/AN/A0 up, 0 downAug 14, 2023
    Mar 31, 2023-$0.19-$0.21-$0.21 - -$0.21+9.52%BeatN/A10 up, 0 downMay 15, 2023
    Dec 31, 2022-$0.18-$0.17-$0.17 - -$0.17-5.88%MissN/A10 up, 0 downMar 30, 2023
    Sep 30, 2022-$0.14-$0.20-$0.20 - -$0.20+30.00%BeatN/A10 up, 0 downNov 14, 2022
    Jun 30, 2022-$0.16-$0.19N/A+15.79%BeatN/AN/A0 up, 0 downAug 15, 2022
    Mar 31, 2022-$0.17-$0.14-$0.14 - -$0.14-21.43%MissN/A10 up, 0 downMay 16, 2022
    Dec 31, 2021-$0.12-$0.19-$0.19 - -$0.19+36.84%BeatN/A1N/AMar 31, 2022
    Sep 30, 2021-$0.14-$0.18-$0.18 - -$0.18+22.22%BeatN/A1N/ANov 15, 2021
    Jun 30, 2021-$0.15-$0.18-$0.18 - -$0.18+16.67%BeatN/A1N/AAug 16, 2021
    Mar 31, 2021-$0.11-$0.17-$0.17 - -$0.17+35.29%BeatN/A1N/AMay 17, 2021
    Dec 31, 2020-$0.13-$0.16-$0.16 - -$0.16+18.75%BeatN/A1N/AMar 31, 2021
    Sep 30, 2020-$0.10-$0.14-$0.14 - -$0.14+28.57%BeatN/A1N/ANov 9, 2020
    Jun 30, 2020-$0.11-$0.07-$0.12 - -$0.07-57.14%MissN/A2N/AAug 10, 2020
    Mar 31, 2020-$0.06-$0.09-$0.11 - -$0.07+33.33%BeatN/A2N/AMay 11, 2020
    Dec 31, 2019-$0.12-$0.06-$0.06 - -$0.06-100.00%MissN/A2N/AMar 16, 2020
    Sep 30, 2019-$0.05-$0.10-$0.10 - -$0.07+50.00%BeatN/A2N/ANov 12, 2019
    Jun 30, 2019-$0.06-$0.12-$0.18 - -$0.06+50.00%BeatN/A2N/AAug 9, 2019
    Mar 31, 2019-$0.20-$0.14-$0.20 - -$0.08-42.86%MissN/A2N/AMay 10, 2019
    Dec 31, 2018-$0.08-$0.08-$0.08 - -$0.080.00%In lineN/A2N/AMar 6, 2019
    Sep 30, 2018-$0.07-$0.09-$0.09 - -$0.09+22.22%BeatN/A1N/ANov 13, 2018
    Jun 30, 2018-$0.11-$0.11-$0.12 - -$0.110.00%In lineN/A2N/AAug 14, 2018
    Mar 31, 2018-$0.12-$0.13-$0.17 - -$0.09+7.69%BeatN/A2N/AMay 11, 2018
    Dec 31, 2017-$0.07-$0.11-$0.12 - -$0.11+36.36%BeatN/A3N/AMar 29, 2018
    Sep 30, 2017-$0.13-$0.15N/A+13.33%BeatN/AN/AN/ANov 7, 2017
    Jun 30, 2017-$0.14-$0.15N/A+6.67%BeatN/AN/AN/AAug 14, 2017
    Mar 31, 2017-$0.15-$0.15N/A0.00%In lineN/AN/AN/AMay 15, 2017
    Dec 31, 2016-$0.12-$0.17N/A+29.41%BeatN/AN/AN/AMar 28, 2017
    Sep 30, 2016-$0.19-$0.22N/A+13.64%BeatN/AN/AN/ANov 8, 2016
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.48, after -$0.76 the year before. It was -$0.75 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.48N/A
    Dec 31, 2024-$0.76N/A
    Dec 31, 2023-$0.74N/A
    Dec 31, 2022-$0.65N/A
    Dec 31, 2021-$0.52N/A
    Dec 31, 2020-$0.40N/A
    Dec 31, 2019-$0.43N/A
    Dec 31, 2018-$0.38N/A
    Dec 31, 2017-$0.49N/A
    Dec 31, 2016-$0.75N/A

    Frequently Asked Questions About GALT

    When is Galectin Therapeutics's next earnings date?

    Galectin Therapeutics's next earnings report is expected for Mar 29, 2027.

    Did GALT beat earnings estimates last quarter?

    No. Galectin Therapeutics reported EPS of -$0.14 for the quarter ended Jun 30, 2026, below the -$0.09 estimate by 55.56%.

    What EPS do analysts expect from GALT next quarter?

    The consensus EPS estimate for Galectin Therapeutics for the quarter ending Dec 31, 2026 is -$0.05 from 3 analysts, with estimates from -$0.05 to -$0.05.

    How often does GALT beat earnings estimates?

    Galectin Therapeutics beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -13.40%.